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Objective: Cognitive remediation (CR) approaches have 
demonstrated to be effective in improving cognitive func-
tions in schizophrenia. However, there is a lack of integrated 
CR approaches that target multiple neuro- and social-cog-
nitive domains with a special focus on the generalization of 
therapy effects to functional outcome. Method: This 8-site 
randomized controlled trial evaluated the efficacy of a novel 
CR group therapy approach called integrated neurocognitive 
therapy (INT). INT includes well-defined exercises to improve 
all neuro- and social-cognitive domains as defined by the 
Measurement And Treatment Research to Improve Cognition 
in Schizophrenia (MATRICS) initiative by compensation 
and restitution. One hundred and fifty-six outpatients with a 
diagnosis of schizophrenia or schizoaffective disorder accord-
ing to DSM-IV-TR or ICD-10 were randomly assigned to 
receive 15 weeks of INT or treatment as usual (TAU). INT 
patients received 30 bi-weekly therapy sessions. Each session 
lasted 90 min. Mixed models were applied to assess changes 
in neurocognition, social cognition, symptoms, and functional 
outcome at post-treatment and at 9-month follow-up. Results: 
In comparison to TAU, INT patients showed significant 
improvements in several neuro- and social-cognitive domains, 
negative symptoms, and functional outcome after therapy 
and at 9-month follow-up. Number-needed-to-treat analyses 
indicate that only 5 INT patients are necessary to produce 
durable and meaningful improvements in functional outcome. 
Conclusions: Integrated interventions on neurocognition and 
social cognition have the potential to improve not only cogni-
tive performance but also functional outcome. These findings 
are important as treatment guidelines for schizophrenia have 
criticized CR for its poor generalization effects.
Introduction
Treatment of schizophrenia patients has moved well 
beyond the reduction of symptoms to the goal of 
functional recovery.1 In addition to symptom remis-
sion, functional recovery demands an adequate level of 
functional outcome in terms of living, work and inter-
personal relationships.2,3 However, despite advances in 
antipsychotic medications and psychological therapies, 
functional recovery rates have not changed substantially 
over the last 25  years.4,5 This has prompted the search 
for factors contributing to poor functional outcome in 
schizophrenia.
A wealth of studies provides evidence for the link between 
neuro-cognitive and functional impairments.6–8 Neuro-
cognitive functions can be defined as processes of linking 
and appraising information9 and have been considered a 
core feature of schizophrenia.10 Against this background, 
the NIMH-Measurement And Treatment Research to 
Improve Cognition in Schizophrenia (MATRICS) ini-
tiative has been founded to identify cognitive domains 
relevant to schizophrenia research and to develop a stan-
dardized cognitive battery to foster the evaluation of 
cognitive enhancing interventions.11–13 For this purpose, 6 
neuro-cognitive domains were defined: speed of process-
ing, attention, verbal learning and memory, visual learning 
and memory, working memory, and reasoning and problem 
solving.14 More recently, considerable research has focused 
on social cognition in schizophrenia that refers to the men-
tal operations underlying social interactions such as the 
perception, interpretation, and generation of responses to 
the intentions, dispositions, and behaviors of others.15–17 
The MATRICS-initiative initially defined 5 social-cognitive 
domains: emotion processing, social perception, theory of 
mind, social attributions, and social schema.16,17 Studies 
reported that social-cognitive functions are related to both 
neurocognition18,19 and functional outcome.20–22
These findings have fueled the interest in cognitive 
remediation therapy (CR) that aims to improve cognitive 
processes with the goal of durability and generalization 
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of these cognitive benefits to functional outcome.23 The 
efficacy of CR has been summarized in several meta-
analyses23–26 with small to moderate effects on cognitive 
domains and functional outcome at post-treatment and 
follow-up. The effect of CR on symptoms was small 
and disappeared at follow-up. However, these beneficial 
results should not mask that CR approaches vary widely 
with regard to their intervention targets with most CR 
approaches targeting either neuro- or social-cognitive 
functions.27 Although the mediating role of social cog-
nition suggests that an integrated treatment of neuro- 
and social cognition may produce better generalization 
effects on functional outcome than neuro- or social-
cognitive therapy alone,28 few approaches have been 
developed that combine neuro- and social-CR.29–32 The 
importance of integrated interventions is also supported 
by meta-analyses on the effectiveness of the Integrated 
Psychological Therapy (IPT)33–35 that demonstrated that 
a combined treatment of neuro- and social-cognitive 
IPT-subprograms produced larger effects on functional 
outcome than neuro-cognitive subprograms alone.36–38 As 
there is no evidence that boosting one cognitive domain 
might improve functional outcome more than another,39 
an approach targeting multiple neuro- and social-cogni-
tive domains may be of benefit for most schizophrenia 
patients. Nevertheless, none of the contemporary CR 
approaches integrates all neuro- and social-cognitive 
MATRICS-domains.24,26,35 Moreover, there is still a lack 
of well-controlled studies assessing the durability and 
generalizability of treatment effects of CR.40,41
Against this background, we developed a CR group 
approach called Integrated Neurocognitive Therapy 
(INT) that combines neuro- and social-CR by targeting 
all 11 MATRICS-domains.42–44 We conducted a random-
ized controlled trial to evaluate the efficacy of INT after 
therapy and after follow-up compared to treatment as 
usual (TAU). Based on the results of IPT36–38 and cur-
rent meta-analyses,23–26 we hypothesized that INT would 
produce significant effects in neuro- and social-cognitive 
domains, symptoms, and functional outcome after ther-
apy and at follow-up.
Methods
Participants
The sample comprised 156 patients with a diagnosis 
of schizophrenia or schizoaffective disorder according 
to DSM-IV-TR or ICD-10. Diagnosis was confirmed 
by their treating psychiatrist or clinical psychologist. 
Additional inclusion criteria were current enrollment in 
an outpatient treatment, age between 18 and 50  years, 
and illness duration of more than 2 years. In accordance 
with the recommendations of the working group confer-
ence on multisite trial design for CR in schizophrenia,45 
study subjects should have IQ scores greater than 80 
(Reduced Wechsler Intelligence Test46). Exclusion criteria 
were neurological disorders, substance dependence and/
or abuse according to DSM-IV-TR or ICD-10 within 
6 months before baseline assessments, and hospitalization 
or changes in medication doses within 2 months before 
baseline assessments. All participants provided written 
informed consent prior to participation under protocols 
approved by the ethics committee at the University of 
Bern.
Procedures
Patients were recruited from 8 outpatient-treatment 
facilities in Switzerland, Germany, and Austria. They 
were randomly assigned to INT or to TAU at each treat-
ment site. An independent statistician carried out the 
randomization procedure for all treatment sites. First, 
computer-generated random numbers were used to gen-
erate 2 groups. Afterwards, these 2 groups were randomly 
assigned to INT or TAU. The main therapy outcomes 
were neuro- and social-cognitive functions; second-
ary outcomes were symptoms and functional outcome. 
A comprehensive battery of these measures was adminis-
tered at baseline prior to randomization, after therapy (ie, 
after 15 weeks), and after a follow-up period of 9 months. 
Trained research assistants who were blind to group allo-
cation carried out all assessments. The assessors reported 
no breaks of blinding. Figure 1 shows the flowchart of 
subject progress.
Interventions
Integrated Neurocognitive Therapy. INT9,42–44 is a manu-
alized CR group approach that consists of 30 sessions 
that were administered by a therapist and a co-therapist 
in groups of 6–8 patients. Sessions took place bi-weekly 
and each session lasted 90 min. Participants received no 
compensation for attending treatment sessions.
All neuro- and social-cognitive MATRICS-domains 
are divided into 4 therapy modules with increasing com-
plexity and emotional strain during the course of INT 
(table 1). Each of the 4 modules consists of neuro- and 
social-cognitive domains. The same didactic structure is 
applied to each domain: (1) INT starts with introductory 
sessions that intend to enhance patients’ understanding 
and awareness of the relevance of the respective cognitive 
domain in everyday life and to increase patients’ insight 
into their own cognitive resources and deficits. (2) In the 
consecutive sessions, patients learn individual coping 
strategies in order to compensate for cognitive impair-
ments, and apply these strategies in interactive group 
exercises. (3) In restitution sessions, patients practice their 
coping strategies in repeated exercises to foster automa-
tization of these compensatory processes. These exercises 
are partially computer-based using the Cogpack program 
(version 5.1, Marker Software, Ladenburg, Germany). 
(4) Finally, homework assignments and in vivo exercises 
serve to promote transfer of the acquired cognitive skills 
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into patients’ daily living context and to maintain treat-
ment effects. Thereby, INT represents both a strategy-
based learning and a drill-and-practice approach.
All therapists were trained in cognitive-behavior ther-
apy methods. Therapist training in INT was provided sys-
tematically by the developers in a 2-day seminar at each 
treatment site. During therapy and follow-up, supervi-
sion was available personally or via telephone or email. 
Supervision was carried out at least fortnightly. Fidelity 
checklists were administered in each session and assured 
adherence to the therapy protocol at all treatment sites. 
Those assigned to INT attended on average 81.1% 
(SD = 13.0%) of the therapy sessions.
INT represents a further development of the cognitive 
parts of IPT but differs from it in that it targets all 11 
neuro- and social-cognitive MATRICS-domains while 
IPT focuses predominantly on the domains of speed of 
processing, attention, reasoning and problem solving as 
well as on emotion and social perception. Furthermore, 
INT uses computerized neuro-cognitive exercises for 
restitution, and has been exclusively designed for outpa-
tient settings. Therefore, the exercises of INT are more 
cognitively and emotionally demanding and are more 
closely linked to personal experiences and everyday life. 
In comparison to INT, IPT seems especially appropriate 
for inpatients with substantial cognitive and psychosocial 
impairments and severe negative symptoms.43,44
Treatment as Usual. INT effects were compared to those 
of  TAU. TAU was defined as standard care including a 
Fig. 1. Flow diagram of subject progress through phases of the randomized controlled trial for the Integrated Neurocognitive Therapy 
(INT) and Treatment As Usual (TAU) group.
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Table 1. Therapy Contents of Integrated Neurocognitive Therapy
Module A
Speed of processing and attention Introduction/education
 Education and self-perception in the target domains (performance-based individual 
cognitive profile)a
 Reference to everyday life and personal experiencesa
 Focus on under-stimulation at work, in leisure, and while reading a book
 Factors influencing the cognitive performance: eg, alertness, medication, interests and 
motivation
Compensation
 Development of individual coping strategies (strategy learning)a to improve speed of 
processing and attention; eg, reduce distraction, self-empowerment and self- 
verbalization, taking a break
Restitution and in vivo exercises
 Practice coping strategies in repeated group exercises, computerized exercises (rehearsal 
learning)a and goal-related in vivo exercises in the focused cognitive domain (to 
support transfer to everyday life)a
Emotion processing Introduction/education
 Emotional influences on perception (filter model)
 Identification and definition of basic emotions and their prototypical characteristics
Compensation
 Affect recognition training following three steps: 1) facial expressions, 2) gestures, 
3) sequences of emotions
Restitution and in vivo exercises
 Repeated training of affect decoding to rely on facts instead of assumptions
Module B
Verbal and visual learning, and memory Introduction/education:
 Distinguishing between different types of memory: short term memory, long term 
memory, prospective memory (in contrast to working memory)
 Memory contents: verbal memory (eg, letters, names) and visual/spatial memory (eg, 
faces, signs)
Compensation
 Learning and individualizing coping strategies; eg, chunking, using all senses, external 
memory aids, gathering more information, categorizing, mnemonic rhyme, internal image
Restitution and in vivo exercises
 Practice strategies in repeated exercises in the lab and in daily life
Social perception and theory of mind Introduction/education
 Identifying key social stimuli (social perception) and taking the perspective of others (ToM)
Compensation
 Social perception training following three steps: 1) gathering information, 
2) interpretation and discussion, 3) assigning a title
 ToM strategies: Distinguish between facts and assumptions when interpreting social 
information, role change, reference to own and others experiences
Restitution and in vivo exercises
 Training of communication skills
Module C
Reasoning and problem solving Introduction/education:
 Focus on cognitive flexibility and concept formation and implementing a problem 
solving model
Compensation
 Planning and problem solving skills training (strategy learning)
 How to find the right words in a conversation (communication training)
Restitution and in vivo exercises
 Practice strategies in repeated exercises in the lab and in daily life
Social schema Introduction/education
 Influence of norms and roles on social behavior and automatic use of social knowledge
Compensation
 Training of social actions dependent on norms and behavioral sequences (social scripts)
 Changing own behavior if  it deviates from the norm
 Coping with social stigma
Restitution and in vivo exercises
 Practice strategies in role plays and in daily life
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broad array of  interventions used in clinical practice for 
schizophrenia patients (eg, medication, individual ther-
apy, case-management). Both INT and TAU patients 
were not allowed to take part in specific group therapies 
that primarily applied other CR techniques, cognitive-
behavioral therapy, social skills therapy or supported 
employment because these interventions may also have 
substantial beneficial effects on neuro- and social-cog-
nitive functions and functional outcome. However, INT 
and TAU patients could receive all other kinds of  psy-
chosocial interventions administered in a group setting 
including music therapy, art therapy, movement/dance 
therapy, case-management, psychoeducation, supportive 
and vocational counseling, and leisure time-groups.
Measures
While commonly used measures in schizophrenia research 
are only described briefly, more detailed information and 
references are provided for rather new assessments in 
schizophrenia patients.
Neurocognition. The neuro-cognitive test battery 
included the following measures commonly applied in 
schizophrenia research: (1) Speed of  processing was 
assessed using the Trail Making Test47 (TMT) Part 
A  (time to completion) and the Controlled Oral Word 
Association Test48 (COWAT) (mean value of  produced 
words per minute); (2) Attention using the Continuous 
Performance Test49 (CPT) (total number of  commission 
errors during the test) and the d250 (number of  correctly 
marked items). The d2 is a paper-and-pencil cancellation 
test that has proven to be a reliable and valid measure 
of  selective attention;50 (3) Verbal learning and memory 
using the Auditory Verbal Learning Test51 (AVLT) (sum-
mary score of  correctly remembered words after each 
trial); (4) Visual learning and memory with the Wechsler 
Memory Scale-Revised Third Edition52 (WMS-R) (total 
number of  correctly recognized items); (5) Working 
memory with the Letter-Number Span53 (LNS) (total 
number of  correctly remembered items); (6) Reasoning 
and problem solving with the Wisconsin Card Sorting 
Test54 (WCST) (total number of  perseverative answers).
Social Cognition. We assessed emotion perception 
through the Picture of Facial Affect Test55 (PFA) and 
the Emotion Recognition Questionnaire56 (Emorec). 
Both measures require the participant to view photo-
graphs of faces and to identify specific basic emotions 
(PFA) or to rate the intensity of the perceived emotion 
on a 5-point Likert scale (Emorec). Friesen and Ekman 
developed this series of photographs.57 The Emorec 
has proven to be a reliable and valid measure of emo-
tion perception.56 The test score of both measures was 
the total number of correct judgments. (2) We adminis-
tered the Schema Component Sequencing Task-Revised58 
(SCST-R) as a computerized measure of social schema. 
The task is to order the component actions of 12 social 
situations in the right sequence using verbal stimuli. The 
dependent variable was the total number of the correctly 
juxtaposed pairs over all situations. (3) The Ambiguous 
Intentions Hostility Questionnaire59 (AIHQ) measures 5 
social-cognitive attribution biases (hostility, anger, blame, 
intention, and aggression). We applied the 5 ambiguous 
situations only as they seem to be most sensitive for attri-
bution biases.59 Two independent raters coded the written 
answers and revealed high average intra-class reliability 
(ICCs = 0.93–0.99).
Module D
Working memory Introduction/education:
 Focus on selective attention and distractibility in terms of over-stimulation in social 
contexts
Compensation
 Behavioral shift (to change from one action to another) and adaptive behavior
 Selective attention skills training while being confronted with emotional strain and 
distraction
 Learning how to avoid distraction during a conversation
Restitution and in vivo exercises
 Practice strategies in repeated exercises and daily life
Social attributions and emotion regulation Introduction/education
 Relationship of one`s own attribution style to emotional strain and over-stimulation
Compensation
 Analyzing one`s own attribution style and the consequences of internal and external 
attributions
 Reattribution: Finding alternative explanations
 Stress-inoculation training and emotion regulation training
Restitution and in vivo exercise
 Practice strategies in repeated exercises in daily life
aThese contents are part of the interventions on each neuro- and social-cognitive domain in all 4 modules.
Table 1. Continued
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Symptoms and Functional Outcome. The Positive and 
Negative Syndrome Scale (PANSS)60 was administered 
to rate negative and positive symptom severity and the 
Global Assessment of Functioning Scale (GAF) of the 
DSM-IV to measure functional outcome. The sample of 
this study comprised schizophrenia outpatients with the 
symptom ratings being in the medium range (table  2). 
Studies indicate that the GAF scale is a valid measure 
of global functional outcome given that patients are 
clinically stable.61 All raters received specific training 
and revealed high inter-rater reliability (ICC = 0.91 for 
PANSS and ICC = 0.92 for GAF).
Statistical Analyses
All analyses were conducted using SPSS 21.0 (SPSS 
Inc). Raw data were checked for normality and outli-
ers. Group comparisons between INT and TAU as well 
as between completers and noncompleters of therapy 
at baseline were performed using chi-square and t-tests. 
With regard to therapy outcomes, we computed com-
posite scores with equal weights using z-transformations 
for “global neurocognition,” “global social cognition,” 
“global symptoms,” and for cognitive domains that were 
assessed by more than one test, that is, “speed of process-
ing,” “attention,” and “emotion perception.” Changes in 
the global composite scores and the assessed cognitive 
domains were analyzed using linear mixed modeling with 
maximum likelihood estimation including all subjects in 
an intent-to-treat analysis. Models included group (INT 
and TAU) and time (baseline, post-therapy, follow-up) as 
well as their interaction (group × time) as fixed effects. 
Additionally, models comprised random intercepts and 
slopes for subjects and treatment sites. A diagonal covari-
ance structure was used as the repeated covariance type 
and a variance components matrix was selected for the 
random effects. Significant interactions were interpreted 
as a differential treatment effect.
Following recent recommendations, we also focused 
on effect sizes.62 Cohen’s d was calculated at post-therapy 
and follow-up using the difference of the respective group 
means divided by their pooled standard deviation.63 
Additionally, we calculated the number-needed-to-treat 
(NNT) for all significant interaction effects at various lev-
els of change (10%–60%) in cognitive, symptomatic, and 
functional outcomes as assessed by single tests.64,65
Results
Baseline Analyses
INT and TAU neither differed significantly in demo-
graphic variables or antipsychotic medication (table  2) 
nor in any outcome variable (table 3). All but 4 patients 
were taking antipsychotic medication (91% atypical 
neuroleptics, 7% typical neuroleptics, 2% mixed), and 7 
patients (4%) received antidepressants (SSRIs) as con-
comitant medication. There were no significant group 
differences in medication doses at baseline, post-therapy, 
and follow-up. Moreover, both groups did not demon-
strate significant changes in their medication doses from 
baseline to post-therapy and follow-up. Completers and 
noncompleters did not differ significantly in demographic 
and outcome variables at post-therapy and follow-up.
Treatment Effects on Neurocognition
Means, SDs, and effect sizes of all therapy outcomes 
are presented in table  3. INT demonstrated significant 
improvements in global neurocognition after therapy 
(F1,172  =  4.45, P  =  0.04, Cohen’s d  =  0.43) but not at 
follow-up (F2,264  =  2.40, P  =  0.09, d  =  0.02). Using the 
TMT and the COWAT as a measure of speed of pro-
cessing, group differences favoring INT were significant 
after therapy (F1,146 = 5.41, P = 0.02, d = 0.41). Moreover, 
INT demonstrated significant improvements in reason-
ing and problem solving at post-therapy (F1,155  =  4.57, 
Table 2. Sample Characteristics of INT and TAU Group
INT group (n = 81) TAU group (n = 75) t/χ2 a P
Age (y), mean (SD) 34.6 (8.5) 33.8 (8.7) 0.6 0.5
Gender (male %) 64.2 74.7 2.0 0.2
IQb mean (SD) 105.6 (10.0) 102.2 (12.3) 1.7 0.1
Duration of illness (y), mean (SD) 10.2 (7.5) 9.9 (7.0) 0.3 0.8
Number of hospitalizations (n) 3.7 (3.3) 4.6 (4.9) −1.2 0.2
Education (y), mean (SD) 11.2 (4.1) 10.8 (4.4) 0.6 0.6
Marital status (%)
 Single 77.5 93.4
 Married 9.9 1.6
 Divorced 12.7 4.9 3.6 0.3
Chlorpromazine equivalent doses, mean (SD) 422.3 (420.9) 456.0 (380.2) −0.5 0.7
Note: INT, integrated neurocognitive therapy; TAU, treatment as usual.
at-Tests for normally distributed variables; χ2-tests for categorical variables.
bReduced Wechsler Intelligence Test46 (WIP).
610
D. R. Mueller et al
T
ab
le
 3
. 
M
ea
su
re
s 
of
 N
eu
ro
co
gn
it
io
n,
 S
oc
ia
l C
og
ni
ti
on
, N
eg
at
iv
e 
Sy
m
pt
om
s,
 a
nd
 F
un
ct
io
na
l O
ut
co
m
e 
at
 B
as
el
in
e,
 A
ft
er
 T
he
ra
py
/A
ft
er
 1
5 
W
ee
ks
, a
nd
 a
t 
9-
M
on
th
 F
ol
lo
w
-U
p
B
as
el
in
e
A
ft
er
 t
he
ra
py
/a
ft
er
 1
5 
w
ee
ks
F
ol
lo
w
-u
p/
af
te
r 
37
 w
ee
ks
IN
T,
 M
ea
n 
(S
D
)
T
A
U
, M
ea
n 
(S
D
)
ta
 (
P
 
va
lu
es
)
IN
T,
 M
ea
n 
(S
D
)
T
A
U
, M
ea
n 
(S
D
)
F
b  (
P
 v
al
ue
s)
C
oh
en
`s
 d
; 
N
N
T
IN
T,
 M
ea
n 
(S
D
)
T
A
U
, M
ea
n 
(S
D
)
F
b  (
P
 v
al
ue
s)
C
oh
en
`s
 d
; 
N
N
T
N
eu
ro
co
gn
it
io
n
−
0.
05
 (
0.
52
)
−
0.
15
 (
0.
58
)
1.
10
 (
0.
27
)
0.
27
 (
0.
48
)
0.
03
 (
0.
62
)
4.
45
* 
(0
.0
4)
0.
43
0.
14
 (
0.
44
)
0.
13
 (
0.
44
)
2.
26
 (
0.
09
)
0.
02
 
S
pe
ed
 o
f 
pr
oc
es
si
ng
: 
T
M
T
 A
 &
 
C
O
W
A
T
−
0.
31
 (
1.
58
)
−
0.
51
 (
1.
69
)
0.
76
 (
0.
45
)
0.
72
 (
1.
53
)
0.
07
 (
1.
66
)
5.
41
* 
(0
.0
2)
0.
41
−
0.
15
 (
1.
14
)
−
0.
03
 (
1.
66
)
1.
40
* 
(0
.2
5)
−
0.
08
 
A
tt
en
ti
on
: 
C
P
T
 a
nd
 
d2
−
0.
07
 (
0.
98
)
−
0.
08
 (
2.
44
)
0.
03
 (
0.
97
)
0.
12
 (
0.
93
)
−
0.
14
 (
1.
56
)
0.
26
 (
0.
61
)
0.
20
0.
39
 (
0.
97
)
0.
30
 (
1.
10
)
6.
78
* 
(0
.0
2)
0.
09
 
V
is
ua
l 
m
em
or
y:
 
W
M
S-
R
6.
09
 (
1.
69
)
6.
07
 (
1.
59
)
0.
07
 (
0.
94
)
6.
49
 (
1.
62
)
6.
46
 (
1.
74
)
0.
00
 (
0.
99
)
0.
01
6.
78
 (
1.
54
)
6.
45
 (
1.
88
)
0.
84
 (
0.
43
)
0.
19
 
V
er
ba
l 
m
em
or
y:
 
A
V
LT
44
.7
8 
(1
0.
47
)
45
.3
4 
(1
1.
23
)
−
0.
32
 (
0.
75
)
45
.2
 (
10
.8
9)
45
.4
0 
(1
2.
73
)
0.
06
 (
0.
81
)
0.
04
50
.2
0 
(1
0.
49
)
47
.9
1 
(1
1.
12
)
3.
61
* 
(0
.0
3)
0.
26
;
10
%
: 1
0.
1
20
%
: 1
0.
4
30
%
: 1
3.
1
40
%
: 1
6.
6
50
%
: 4
4.
4
60
%
: 6
0.
9
 
W
or
ki
ng
 
m
em
or
y:
 
L
N
S
13
.1
2 
(3
.8
1)
12
.3
6 
(4
.2
4)
1.
17
 (
0.
24
)
13
.5
0 
(2
.8
9)
12
.5
2 
(3
.4
2)
0.
29
 (
0.
59
)
0.
26
13
.3
6 
(2
.9
0)
12
.5
4 
(3
.3
0)
0.
21
 (
0.
81
)
0.
16
 
R
ea
so
ni
ng
 
&
 p
ro
bl
em
 
so
lv
in
g:
 
W
C
ST
−
36
.4
9 
(2
5.
93
)
−
36
.3
6 
(3
0.
74
)
0.
03
 (
0.
98
)
−
28
.8
3 
(2
5.
93
)
−
36
.7
 (
29
.3
7)
4.
57
* 
(0
.0
3)
0.
32
;
−
28
.5
6 
(2
2.
64
)−
29
.0
8 
(2
0.
78
)
3.
23
 (
0.
05
)
0.
03
10
%
: 1
2.
8
20
%
: 8
.0
30
%
: 8
.2
40
%
: 8
.9
50
%
: 9
.7
60
%
: 1
1.
3
S
oc
ia
l C
og
ni
ti
on
−
0.
22
 (
2.
40
)
−
0.
16
 (
2.
42
)
−
0.
13
 (
0.
90
)
0.
71
 (
2.
23
)
−
0.
06
 (
2.
59
)
7.
05
**
 (<
0.
01
)
0.
32
0.
63
 (
2.
26
)
0.
08
 (
2.
39
)
5.
04
**
 (<
0.
01
)
0.
24
 
E
m
ot
io
n 
pe
rc
ep
ti
on
: 
P
FA
 &
 
E
m
or
ec
−
0.
20
 (
1.
78
)
−
0.
10
 (
1.
64
)
−
0.
36
 (
0.
72
)
0.
41
 (
1.
65
)
−
0.
10
 (
1.
69
)1
0.
97
**
 (<
0.
01
)
0.
31
0.
42
 (
1.
63
)
0.
01
 (
1.
79
)
6.
63
**
 (0
.0
2)
0.
24
611
One-Year Randomized Controlled Trial and Follow-Up of Integrated Neurocognitive Therapy for Schizophrenia Outpatients
B
as
el
in
e
A
ft
er
 t
he
ra
py
/a
ft
er
 1
5 
w
ee
ks
F
ol
lo
w
-u
p/
af
te
r 
37
 w
ee
ks
IN
T,
 M
ea
n 
(S
D
)
T
A
U
, M
ea
n 
(S
D
)
ta
 (
P
 
va
lu
es
)
IN
T,
 M
ea
n 
(S
D
)
T
A
U
, M
ea
n 
(S
D
)
F
b  (
P
 v
al
ue
s)
C
oh
en
`s
 d
; 
N
N
T
IN
T,
 M
ea
n 
(S
D
)
T
A
U
, M
ea
n 
(S
D
)
F
b  (
P
 v
al
ue
s)
C
oh
en
`s
 d
; 
N
N
T
 
S
oc
ia
l 
sc
he
m
a:
 
SC
ST
-R
61
.9
4 
(1
1.
34
)
59
.7
6 
(1
4.
71
)
−
0.
13
 (
0.
90
)
64
.1
0 
(1
1.
85
)
59
.5
6 
(1
5.
80
)
3.
92
* 
(0
.0
4)
0.
33
;
64
.2
6 
(1
1.
22
)
62
.4
4 
(1
2.
83
)
1.
57
 (
0.
21
)
0.
15
10
%
: 6
.4
20
%
: 6
.3
30
%
: 6
.6
40
%
: 9
.0
50
%
: 1
1.
4
60
%
: 1
7.
9
 
A
tt
ri
bu
ti
on
s:
 
A
IA
Q
−
0.
40
 (
3.
78
)
−
0.
17
 (
4.
40
)
−
0.
35
 (
0.
73
)
0.
26
 (
3.
23
)
0.
32
 (
3.
51
)
0.
12
 (
0.
74
)
−
0.
02
0.
17
 (
3.
66
)
−
0.
16
 (
3.
75
)
0.
34
 (
0.
71
)
0.
09
S
ym
pt
om
s
−
0.
16
 (
1.
62
)
−
0.
42
 1
.6
4
0.
97
 (
0.
33
)
0.
78
 (
1.
48
)
−
0.
19
 1
.7
2
9.
15
**
 (<
0.
01
)
0.
60
0.
79
 (
1.
62
)
0.
06
 (
1.
64
)
5.
19
**
 (<
0.
01
)
0.
45
 
N
eg
at
iv
e:
 
PA
N
SS
−
16
.4
4 
(5
.8
7)
−
17
.8
4 
(5
.9
9)
−
1.
46
 (
0.
15
)
−
14
.0
9 
(5
.2
7)
−
17
.5
6 
(5
.3
8)
9.
89
**
 (<
0.
01
)
0.
66
;
−
13
.6
8 
(5
.0
4)
−
16
.2
9 
(6
.1
2)
5.
09
**
 (<
0.
01
)
0.
48
;
10
%
: 3
.9
10
%
: 6
.1
20
%
: 3
.9
20
%
: 5
.0
30
%
: 4
.0
30
%
: 5
.3
40
%
: 4
.1
40
%
: 5
.4
50
%
: 5
.8
50
%
: 5
.6
60
%
: 9
.4
60
%
: 5
.8
 
Po
si
ti
ve
: 
PA
N
SS
−
15
.4
8 
(5
.0
6)
−
15
.6
7 
(4
.4
5)
0.
24
 (
0.
81
)
−
13
.1
3 
(4
.1
4)
−
14
.7
9 
(5
.0
7)
4.
49
* 
(0
.0
4)
0.
36
;
−
12
.8
2 
(4
.6
7)
14
.0
7 
(4
.0
6)
2.
75
 (
0.
07
)
0.
28
10
%
: 1
0.
0
20
%
: 3
3.
3
30
%
: 1
1.
1
40
 %
: 5
0.
0
50
%
: 2
0.
0
60
%
 1
00
.0
F
un
ct
io
na
l 
O
ut
co
m
e:
 
G
A
F
49
.1
2 
(8
.1
2)
48
.4
0 
(8
.9
0)
0.
52
 (
0.
60
)
52
.6
0 
(8
.3
0)
49
.5
7 
(8
.7
7)
4.
71
* 
(0
.0
3)
0.
40
;
55
.4
1 
(7
.3
3)
50
.7
2 
(9
.4
2)
8.
17
**
 (<
0.
01
)
0.
71
;
10
%
: 6
.4
10
%
: 3
.8
20
%
: 7
.2
20
%
: 3
.6
30
%
: 8
.7
30
%
: 3
.9
40
%
: 9
.9
 
40
%
: 4
.3
50
%
: 1
5.
2
50
%
: 5
.3
60
%
: 4
1.
5
60
%
: 8
.8
N
ot
e:
 A
IH
Q
, A
m
bi
gu
ou
s 
In
te
nt
io
ns
 H
os
ti
lit
y 
Q
ue
st
io
nn
ai
re
59
; A
V
LT
, A
ud
it
or
y 
V
er
ba
l L
ea
rn
in
g 
T
es
t5
1 ; 
C
O
W
A
T,
 C
on
tr
ol
le
d 
O
ra
l W
or
d 
A
ss
oc
ia
ti
on
 T
es
t4
8 ; 
C
P
T,
 C
on
ti
nu
ou
s 
P
er
fo
rm
an
ce
 T
es
t4
9 ; 
d2
, A
uf
m
er
ks
am
ke
it
s-
B
el
as
tu
ng
s-
T
es
t5
0 ; 
E
m
or
ec
, E
m
ot
io
n 
R
ec
og
ni
ti
on
 Q
ue
st
io
nn
ai
re
56
; G
A
F,
 G
lo
ba
l A
ss
es
sm
en
t 
of
 F
un
ct
io
ni
ng
 S
ca
le
; I
N
T,
 I
nt
eg
ra
te
d 
N
eu
ro
co
gn
it
iv
e 
T
he
ra
py
; L
N
S,
 L
et
te
r-
N
um
be
r 
Sp
an
53
; P
A
N
SS
, P
os
it
iv
e 
an
d 
N
eg
at
iv
e 
Sy
nd
ro
m
e 
Sc
al
e,
 n
eg
at
iv
e 
sy
m
pt
om
 s
ub
sc
al
e6
0 ; 
P
FA
, P
ic
tu
re
 o
f 
F
ac
ia
l A
ff
ec
t 
T
es
t5
7 ; 
SC
ST
-R
, S
oc
ia
l C
om
po
ne
nt
 S
eq
ue
nc
in
g 
T
as
k-
R
ev
is
ed
58
; T
A
U
, T
re
at
m
en
t 
A
s 
U
su
al
; T
M
T,
 T
ra
il 
M
ak
in
g 
T
es
t,
 P
ar
t 
A
47
; W
C
ST
, W
is
co
ns
in
 C
ar
d 
So
rt
in
g 
T
es
t5
4 ; 
W
M
S-
R
, 
W
ec
hs
le
r 
M
em
or
y 
Sc
al
e-
R
ev
is
ed
.52
 B
ol
d 
le
tt
er
s 
in
di
ca
te
 s
ig
ni
fic
an
t 
gr
ou
p 
×
 t
im
e 
in
te
ra
ct
io
n 
ef
fe
ct
s;
 A
ll 
ef
fe
ct
 s
iz
es
 a
nd
 t
es
t 
sc
or
es
 a
re
 p
re
se
nt
ed
 in
 a
 w
ay
 t
ha
t 
hi
gh
er
 s
co
re
s 
in
di
ca
te
 m
or
e 
im
pr
ov
em
en
ts
 o
r 
be
tt
er
 p
er
fo
rm
an
ce
 in
 t
he
 r
es
pe
ct
iv
e 
m
ea
su
re
. C
oh
en
`s
 d
 h
as
 b
ee
n 
ca
lc
ul
at
ed
 u
si
ng
 t
he
 fo
llo
w
in
g 
fo
rm
ul
a 
af
te
r 
th
er
ap
y 
an
d 
at
 fo
llo
w
-u
p6
3,
66
: 
E
ff
ec
t 
si
ze
 (
d)
 =
 (
M
IN
T
–M
T
A
U
)/
SD
po
ol
ed
; M
IN
T
 in
di
ca
te
s 
th
e 
m
ea
n 
fo
r 
th
e 
IN
T
 g
ro
up
; M
T
A
U
 in
di
ca
te
s 
th
e 
m
ea
n 
fo
r 
th
e 
T
A
U
-g
ro
up
; S
D
po
ol
ed
 in
di
ca
te
s 
th
e 
po
ol
ed
 s
ta
nd
ar
d 
de
vi
at
io
n 
fo
r 
th
e 
tw
o 
gr
ou
ps
.63
 A
lp
ha
 c
oe
ffi
ci
en
ts
 fo
r 
co
gn
it
iv
e 
co
m
po
si
te
 s
co
re
s:
 a
tt
en
ti
on
 (
0.
54
),
 e
m
ot
io
n 
pe
rc
ep
ti
on
 (
0.
60
),
 s
pe
ed
 (
0.
55
),
 n
eu
ro
co
gn
it
io
n 
(0
.5
3)
, s
oc
ia
l c
og
ni
ti
on
 (
0.
49
).
a t
 T
es
ts
 fo
r 
no
rm
al
ly
 d
is
tr
ib
ut
ed
 v
ar
ia
bl
es
.
b F
- 
an
d 
P
-v
al
ue
s 
fo
r 
gr
ou
p 
×
 t
im
e 
in
te
ra
ct
io
n 
ef
fe
ct
s.
*P
 <
 0
.0
5;
 *
*P
 <
 0
.0
1.
T
ab
le
 3
. 
C
on
ti
nu
ed
612
D. R. Mueller et al
P  =  0.03, d  =  0.32, NNT ≥ 8.0) while significant treat-
ment effects at follow-up could be detected in verbal 
memory (F2,149 = 3.61, P = 0.03, d = 0.26, NNT ≥ 10.1) 
and attention (F2,106 = 6.78, P = 0.02, d = 0.09). No sig-
nificant group-by-time interactions were found for visual 
and working memory either at post-therapy or follow-up 
(table 3).
Treatment Effects on Social Cognition
INT produced significantly larger effects in global social 
cognition than TAU at both post-therapy (F1,130 = 7.05, 
P = 0.009, d = 0.32) and at 9-month follow-up (F2,122 = 5.04, 
P = 0.008, d = 0.24) (table 3). With regard to the assessed 
social-cognitive domains, INT demonstrated significantly 
larger improvements than TAU after therapy in emotion 
perception (F1,222 = 10.97, P = 0.001, d = 0.31) and social 
schema (F1,148 = 3.94, P = 0.04, d = 0.33, NNT ≥ 17,9). 
These beneficial effects could be maintained at follow-up 
for emotion perception (F2,124 = 6.63, P = 0.02; d = 0.24) 
but not for social schema. Both groups did not differ in 
their attribution styles after therapy and at-follow-up.
Treatment Effects on Symptoms and Functional 
Outcome
After therapy, INT demonstrated significant reductions 
in negative symptoms (F1,151 = 9.98, P = 0.02, d = 0.66, 
NNT ≥ 3.9) and positive symptoms (F1,141 = 4.49, P = 0.04, 
d = 0.36, NNT ≥ 10.0). These favorable effects on negative 
symptoms could be maintained at follow-up (F2,170 = 5.09, 
P = 0.01, d = 0.40, NNT ≥ 5.0) but the effect on positive 
symptoms was no longer significant. This is reflected by 
an overall significant global symptom score (F1,141 = 9.15, 
P = 0.002, d = 0.60) that slightly decreased at follow-up 
(F2,146 = 5.19, P = 0.007, d = 0.45). Notably, INT also pro-
duced significant improvements in functional outcome 
(F1,150 = 5.09, P = 0.03, d = 0.40, NNT ≥ 5.0) compared 
to TAU that even increased until follow-up (F2,187 = 8.17, 
P < 0.01, d = 0.71, NNT ≥ 3.6).
All effect sizes (Cohen’s d) for cognitive, symptomatic 
and functional outcomes were in the small to moderate 
range (table 3).66 Notably, there was no substantial vari-
ability between treatment sites in all outcome variables as 
indicated by nonsignificant Wald-tests (all Z ≤ 1.64, all 
P > 0.05).
Discussion
This international multisite trial evaluated a novel group 
therapy for schizophrenia outpatients that targets all 
neuro- and social-cognitive domains as defined by the 
MATRICS-initiative.14,16,17 As hypothesized, we found 
that INT showed significant gains in some neuro- and 
social-cognitive domains, symptoms, and functional out-
come compared with TAU.
After treatment, INT resulted in significant improve-
ments in both global neurocognition and social cognition 
as well as in the directly targeted neuro- and social-cognitive 
domains of speed of processing, reasoning and problem 
solving, emotion perception, and social schema. However, 
the respective effects sizes were only in the small to mod-
erate range. The positive effects on these neuro-cognitive 
domains and on emotion perception are in accordance 
with recent meta-analyses.24–27 At 9-month follow-up, 
additional significant improvements in verbal memory 
and attention could be detected. In contrast, no significant 
effect on working and visual memory was evident either 
after treatment or at follow-up. This may be due to a “ceil-
ing” effect as our sample demonstrated mean baseline val-
ues in the LNS that were as high as those after therapy 
in the normative MATRICS-sample.12,13 Alternatively, a 
longer therapy duration may be necessary to improve these 
memory domains because treatments that produced sig-
nificant effects on working31,67 and visual memory32 com-
pleted substantially more hours of practicing exercises 
than INT. Moreover, one of these successful therapy pro-
grams67 additionally targeted early perceptual processes 
because they were found to have impact on higher order 
neuro-cognitive functions.68,69 This may have optimized the 
effect of neuro-CR in particular on memory functions and 
may be a complementary future treatment target for INT.
Regarding social cognition, our positive effects on 
emotion perception replicate the results of other stud-
ies.27,41 The significant improvements in social schema 
extend the current literature and are of considerable sig-
nificance because they suggest that even more complex 
social-cognitive operations are amenable to treatment. 
Furthermore, this effect on social schema is of special 
interest as social schema was found to be a more power-
ful mediator between neurocognition and functional out-
come than other social-cognitive domains.23
Another important finding of  our study was that INT 
produced robust and durable generalization effects on 
functional outcome as assessed by the GAF that even 
increased over time. The effect size at follow-up was gen-
erally larger than in a previous meta-analysis24 and was 
associated with low NNT values: As few as 5 patients 
need to receive INT to improve long-term functional 
outcome by 10%–50%. These generalization effects may 
reflect the benefit of  integrated interventions. This seems 
to be due to the fact that intact neuro-cognitive func-
tions represent a necessary prerequisite for social cog-
nition and, in turn, for functional outcome.70 Thereby, 
neuro-cognitive interventions may potentiate the impact 
of  social-cognitive interventions on functional outcome. 
Importantly, neuro-CR alone is not sufficient to improve 
functional outcome, most likely because social cog-
nition has an even stronger relationship to functional 
outcome than neurocognition,18 and explains additional 
variance of  functional outcome beyond neurocogni-
tion.23 Therefore, intact social-cognitive functions may 
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be necessary to generalize neuro-cognitive improve-
ments to functional outcome. As a certain time inter-
val must elapse for one variable to have an effect on 
another in order to imply a change mechanism,71,72 the 
temporal result pattern we found, ie, significant neuro-, 
social-cognitive and functional improvements at post-
therapy that could be maintained for social cognition 
and that even increased for functional outcome at 
follow-up, are in line with our assumption that neuro-
cognitive improvements produced during therapy could 
have functioned as a mediator for social-cognitive and 
functional improvements at follow-up. However, this 
result pattern is also in line with the alternative expla-
nation that social cognition and other mediators may 
have driven functional improvements independently 
from neuro-cognitive improvements. Therefore, these 2 
explanations need to be tested by the means of  longi-
tudinal structural equation modeling in future studies 
and require the assessment of  all outcome variables at 
several times to disentangle the complex change mecha-
nisms of  INT and CR in general.
The significantly reduced severity of negative symp-
toms found in INT after therapy and at follow-up may 
also be the result of neuro- and social-cognitive improve-
ments because negative symptoms seem to mediate the 
relationship between cognitive functions and functional 
outcome.73,74 This is in line with our own results that dem-
onstrated that social cognition, negative symptoms, and 
social skills functioned as important mediators between 
neurocognition and functional outcome in the INT group 
which resulted in a significant indirect effect. Thus, these 
mediators may have potentiated the beneficial effect of 
neuro-cognitive improvements on functional outcome.75 
Alternatively, it is possible that the group participation 
had a salutary effect on negative symptoms because these 
reductions in negative symptoms were also found in other 
integrated group therapy approaches76,77 but not in com-
puterized integrated treatments.31,32 Furthermore, other 
studies78 showed that self-efficacy beliefs about cognitive 
abilities can have an impact on motivation to perform 
tasks and can change with successful performance. Other 
recent research by Grant and Beck79 has demonstrated 
that defeatist performance beliefs also act as mediator 
between neurocognition, negative symptoms, and func-
tional outcome. Therefore, improvements in self-efficacy 
and defeatist beliefs during INT may also have contrib-
uted to improvements in negative symptoms and func-
tional outcome which needs to be investigated in future 
studies. The fact that positive symptoms improved only at 
post-therapy but not at follow-up may indicate that these 
improvements in negative symptoms are not only a by-
product of a general symptomatic remission but a change 
mechanism in itself.
Our clinical impressions suggest that INT is a feasible 
and well-accepted treatment as indicated by the relatively 
high attendance rate of 81.1% over 30 sessions and the 
low drop-out rate of 10.0% at the end of the intervention. 
This point of view is also supported by the fact that INT 
patients received no travel compensation and were not 
paid for attending therapy sessions. The high acceptabil-
ity of INT may be due to the fact that INT puts strong 
emphasis on the enhancement and maintenance of intrin-
sic motivation, by taking patients’ daily-living experiences 
into account, and by using engaging therapy materials 
with various degrees of difficulty. INT-therapists contin-
uously support group processes to foster group cohesion 
which may also have prevented dropouts.43 Furthermore, 
therapy effects of INT did not differ in all outcome vari-
ables between the 8 treatment sites. Thus, high treatment 
fidelity can be assumed.
Our study had several limitations. As we have not for-
mally assessed medication adherence, we cannot rule 
out its potential impact on the outcomes. We used only 
chart reviews for study inclusion. However, the reliability 
of the psychiatric diagnoses could have been enhanced 
by combining chart reviews with structured diagnostic 
interviews.80 Moreover, our participants were generally 
younger and more intelligent than other schizophrenia 
samples which may limit the generalization effects of 
INT and suggests that the efficacy of INT needs to be 
investigated in other samples in the future. We adminis-
tered the GAF scale as a measure of functional outcome. 
Although it is widely used and seems appropriate in 
samples of stable patients,61 it may be confounded with 
symptom severity and may not be very sensitive for psy-
chosocial changes.81 Thus, the GAF scale is not appropri-
ate to assess functional recovery. Therefore, it would have 
been useful to include more measures of this domain and 
it should be complemented or replaced by a purer func-
tional measure. Moreover, we did not use the MATRICS 
Consensus Cognitive Battery (MCCB) because it was 
published after we had started this study. Our social-cog-
nitive assessments were restricted to emotion perception, 
social schema, and attributions due to the poor suitability 
of measures with adequate psychometric properties and 
sufficient sensitivity to change17 when we designed the 
study. Another limitation is the absence of an active con-
trol group. However, a previous meta-analysis found no 
impact of the control type on the effect size of improve-
ments.26 While active control groups are crucial to iden-
tify essential treatment elements, the comparison with 
TAU is a necessary first step to evaluate the efficacy of 
a novel therapy like INT.24 However, the group modal-
ity, additional therapeutic attention, and alliance with the 
INT therapists could have indirectly influenced the out-
comes of interest. Mixed modeling allowed us to take the 
hierarchical nature of the data into account and revealed 
no substantial variability between treatment sites, which 
supports the effectiveness of INT. However, it would be 
valuable to collect data on the group (eg, group composi-
tion) and therapist (eg, expertise) level in future studies, 
and to enter them into the analyses.
614
D. R. Mueller et al
In summary, despite these limitations, our results sug-
gest that INT is a feasible and effective new group therapy 
approach with the potential to improve functional out-
come in schizophrenia outpatients. A design with active 
and passive control conditions, a direct comparison of 
individual and group setting and of various durations 
of CR may further elucidate factors that are crucial for 
transfer to functional outcome.
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